Antikoagulation bei perkutaner Koronarintervention – Update 2017

Prä-, peri- und postinterventionell ist die Antikoagulation ein wesentlicher Aspekt der medikamentösen Behandlung der koronaren Herzerkrankung. Dieser Beitrag zeigt auf, welche antithrombozytären und antikoagulatorischen Strategien bei Patienten mit perkutaner Koronarintervention auf Basis der aktuellsten Leitlinien und Studiendaten empfohlen werden.

Schlüsselwörter

DAPT, duale Thrombozytenaggregationshemmung - PCI, perkutane koronare Intervention - DAPT-Score - PRECISE-DAPT-Score - Tripel-Therapie

• Literatur

• 1 Sundström J, Hedberg J, Thuresson M. et al. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study. Circulation 2017; 136: 1183-1192 doi:10.1161/CIRCULATIONAHA.117.028321
• 2 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
• 3 Bonaca MP, Bhatt DL, Cohen M. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800 doi:10.1056/NEJMoa1500857
• 4 Morrow DA, Braunwald E, Bonaca MP. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413 doi:10.1056/NEJMoa1200933
• 5 Rothberg MB, Celestin C, Fiore LD. et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143: 241-250
• 6 Dlott JS, George RA, Huang X. et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014; 129: 1407-1414 doi:10.1161/CIRCULATIONAHA.113.002601
• 7 Sørensen R, Hansen ML, Abildstrom SZ. et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967-1974 doi:10.1016/S0140-6736(09)61751-7
• 8 Valgimigli M, Bueno H, Byrne RA. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2017;
• 9 Ibanez B, James S, Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2017;
• 10 Nef HM, Abdel-Wahab M, Achenbach S. et al. Medikamentenfreisetzende Koronarstents/-scaffolds und medikamentenbeschichtete Ballonkatheter. Kardiologe 2017;
• 11 Byrne RA, Serruys PW, Baumbach A. et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J 2015; 36: 2608-2620 doi:10.1093/eurheartj/ehv203
• 12 Cannon CP, Harrington RA, James S. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283-293 doi:10.1016/S0140-6736(09)62191-7
• 13 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015
• 14 Sibbing D, Aradi D, Jacobshagen C. et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017; 390: 1747-1757 doi:10.1016/S0140-6736(17)32155-4
• 15 Montalescot G, Bolognese L, Dudek D. et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010 doi:10.1056/NEJMoa1308075
• 16 Westman PC, Lipinski MJ. et al. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Cardiovasc Revasc Med 2017; 18: 79-85 doi:10.1016/j.carrev.2016.10.005
• 17 Bonaca MP, Bhatt DL, Cohen M. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800 doi:10.1056/NEJMoa1500857
• 18 Capodanno D, Angiolillo DJ. Tailoring duration of DAPT with risk scores. Lancet 2017; 389(10073): 987-989 doi:10.1016/S0140-6736(17)30591-3
• 19 Kereiakes DJ, Yeh RW, Massaro JM. et al. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol 2016; 67: 2492-2502 doi:10.1016/j.jacc.2016.03.485
• 20 Costa F, van Klaveren D, James S. et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389: 1025-1034 doi:10.1016/S0140-6736(17)30397-5
• 21 Erlinge D, Omerovic E, Fröbert O. et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med 2017; 377: 1132-1142 doi:10.1056/NEJMoa1706443
• 22 Majure DT, Aberegg SK. Fondaparinux versus enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 2829
• 23 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962 doi:10.1016/S0140-6736(13)62343-0
• 24 Gibson CM, Chakrabarti AK. et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS2 TIMI 51. J Am Coll Cardiol 2013; 62: 286-290 doi:10.1016/j.jacc.2013.03.041
• 25 Hess CN, James S, Lopes RD. et al. Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. J Am Coll Cardiol 2015; 66: 777-787 doi:10.1016/j.jacc.2015.06.027
• 26 Costopoulos C, Niespialowska-Steuden M, Kukreja N. et al. Novel oral anticoagulants in acute coronary syndrome. Int J Cardiol 2013; 167: 2449-2455 doi:10.1016/j.ijcard.2012.08.014
• 27 Eikelboom JW, Connolly SJ, Bosch J. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319-1330 doi:10.1056/NEJMoa1709118
• 28 Dewilde WJ, Oirbans T, Verheugt FW. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115 doi:10.1016/S0140-6736(12)62177-1
• 29 Gibson CM, Mehran R, Bode C. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423-2434 doi:10.1056/NEJMoa1611594
• 30 Cannon CP, Bhatt DL, Oldgren J. et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377: 1513-1524 doi:10.1056/NEJMoa1708454